Differential expression and prognostic role of selected genes in colorectal cancer patients

Anticancer Research

Volumn 33, Issue 11, 2013, Pages 4855-4866

  Pitule, Pavel ^a   Vycital, Ondrej ^b   Bruha, Jan ^b   Novak, Petr ^b   Hosek, Petr ^a,c   Treska, Vladislav ^b   Hlavata, Ivona ^d   Soucek, Pavel ^a,d   Kralickova, Milena ^a   Liska, Vaclav ^a,b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b Teaching Hospital and Medical School ^*  (Czech Republic)

^c CZECH TECHNICAL UNIVERSITY IN PRAGUE   (Czech Republic)

^d NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

Author keywords

Colorectal cancer; Gene expression; Prognostic markers

Indexed keywords

ACYL COA SYNTHETASE LONG CHAIN FAMILY MEMBER 5 GENE; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CLAUDIN 23 GENE; COLLAGEN TRIPLE HELIX REPEAT CONTAINING 1 GENE; COLORECTAL CANCER; CONTROLLED STUDY; DISEASE FREE INTERVAL; FEMALE; GENE; GENE EXPRESSION; HUMAN; LEUCINE RICH REPEAT CONTAINING G PROTEIN COUPLED RECEPTOR 5 GENE; MAJOR CLINICAL STUDY; MALE; MESODERM INDUCTION EARLY RESPONSE 1 FAMILY MEMBER 3 GENE; MIDDLE AGED; MITOGEN ACTIVATED PROTEIN KINASE 1 GENE; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SOLUTE CARRIER FAMILY 26 MEMBER 2 GENE; UPREGULATION; VERSICAN GENE; VISININ LIKE 1 GENE;

COLORECTAL CANCER; GENE EXPRESSION; PROGNOSTIC MARKERS;

AGED; CHEMOTHERAPY, ADJUVANT; COLON; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; PALLIATIVE CARE; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84891361930     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
2. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N: Colorectal cancer. Lancet 375 (9719): 1030-1047, 2010.
3. Armaghany T, Wilson JD, Chu Q and Mills G: Genetic alterations in colorectal cancer. Gastrointest Cancer Res 5: 19-27, 2012.
4. Aparo S and Goel S: Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy. Crit Rev Oncol Hematol 83(1): 47-58, 2012.
5. Ng K and Zhu AX: Targeting the epidermal growth factor receptor in metastatic colorectal cancer. Crit Rev Oncol Hematol 65: 8-20, 2008.
6. Lièvre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Côté JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F and Laurent-Puig P: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006.
7. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I and Van Cutsem E: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345, 2004.
8. Vecchione L, Jacobs B, Normanno N, Ciardiello F and Tejpar S: EGFR-targeted therapy. Exp Cell Res 317: 2765-2771, 2011.
9. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier Pet P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M and Tejpar S: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis. Lancet Oncol 11: 753-762, 2010.
10. Grossmann AH and Samowitz WS: Epidermal growth factor receptor pathway mutations and colorectal cancer therapy. Arch Pathol Lab Med 135: 1278-1282, 2011.
11. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I and Kerr D: Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9: 489-499, 2009.
12. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH, Selby P, Meade AM, Stephens RJ, Parmar MK and Seymour MT: Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial. J Clin Oncol 26(16): 2690-2698, 2008.
13. Kleivi K, Lind GE, Diep CB, Meling GI, Brandal LT, Nesland JM, Myklebost O, Rognum TO, Giercksky KE, Skotheim RI and Lothe RA: Gene expression profiles of primary colorectal carcinomas, liver metastases, and carcinomatoses. Mol Cancer 6: 2, 2007.
14. Kwong KY, Bloom GC, Yang I, Boulware D, Coppola D, Haseman J, Chen E, McGrath A, Makusky AJ, Taylor J, Steiner S, Zhou J, Yeatman TJ and Quackenbush J: Synchronous global assessment of gene and protein expression in colorectal cancer progression. Genomics 2: 142-158, 2005.
15. Hlavata I, Mohelnikova-Duchonova B, Vaclavikova R, Liska V, Pitule P, Novak P, Bruha J, Vycital O, Holubec L, Treska V, Vodicka P and Soucek P: The role of ABC transporters in progression and clinical outcome of colorectal cancer. Mutagenesis 2: 187-96, 2012.
16. Rozen S and Skaletsky HJ: Primer3. 1998. Code available at http://www-genome.wi.mit.edu/genome-software/other/primer3.html.
17. Liska V, Holubec L Jr, Treska V, Skalicky T, Sutnar A, Kormunda S, Pesta M, Finek J, Rousarova M and Topolcan O: Dynamics of serum levels of tumour markers and prognosis of recurrence and survival after liver surgery for colorectal liver metastases. Anticancer Res 27(4C): 2861-2864. 2007.
18. Braunewell KH, Spilker C, Behnisch T and Gundelfinger ED: The neuronal calcium-sensor protein VILIP modulates cyclic AMP accumulation in stably transfected C6 glioma cells: Amino-terminal myristoylation determines functional activity. J Neurochem 68(5): 2129-39, 1997.
19. Braunewell KH: The visinin-like proteins VILIP-1 and VILIP-3 in Alzheimer's disease - old wine in new bottles. Front Mol Neurosci 5: 20, 2012.
20. Tarawneh R, D'Angelo G, Macy E, Xiong C, Carter D, Cairns NJ, Fagan AM, Head D, Mintun MA, Ladenson JH, Lee JM, Morris JC and Holtzman DM: Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease. Ann Neurol 70(2): 274-285, 2011.
21. Xie Y, Chan H, Fan J, Chen Y, Young J, Li W, Miao X, Yuan Z, Wang H, Tam PK and Ren Y: Involvement of visinin-like protein-1 (VSNL-1) in regulating proliferative and invasive properties of neuroblastoma. Carcinogenesis 28(10): 2122-2130, 2007.
22. Fu J, Fong K, Bellacosa A, Ross E, Apostolou S, Bassi DE, Jin F, Zhang J, Cairns P, Ibañez de Caceres I, Braunewell KH and Klein-Szanto AJ: VILIP-1 down-regulation in non-small cell lung carcinomas: Mechanisms and prediction of survival. PLoS One 3(2): e1698, 2008.
23. Schönrath K, Klein-Szanto AJ and Braunewell KH: The putative tumour suppressor VILIP-1 counteracts epidermal growth factor-induced epidermal-mesenchymal transition in squamous carcinoma cells. PLoS One 7(3): e33116, 2012.
24. Goulet AC, Watts G, Lord JL and Nelson MA: Profiling of selenomethionine responsive genes in colon cancer by microarray analysis. Cancer Biol Ther 6(4): 494-503, 2007.
25. Findeisen P, Röckel M, Nees M, Röder C, Kienle P, Von Knebel Doeberitz M, Kalthoff H and Neumaier M: Systematic identification and validation of candidate genes for detection of circulating tumour cells in peripheral blood specimens of colorectal cancer patients. Int J Oncol 33(5): 1001-1010, 2008.
26. Akagi T, Hijiya N, Inomata M, Shiraishi N, Moriyama M and Kitano S. Visinin-like protein-1 overexpression is an indicator of lymph node metastasis and poor prognosis in colorectal cancer patients. Int J Cancer 131(6): 1307-1317, 2012.
27. Fu J, Jin F, Zhang J, Fong K, Bassi DE, Lopez De Cicco R, Ramaraju D, Braunewell KH, Conti C, Benavides F and Klein-Szanto AJ: VILIP-1 expression in vivo results in decreased mouse skin keratinocyte proliferation and tumour development. PLoS One 5(4): e10196, 2010.
28. Zhang Z, Zhang J, Miao L, Liu K, Yang S, Pan C and Jiao B: Interleukin-11 promotes the progress of gastric carcinoma via abnormally expressed versican. Int J Biol Sci 8(3): 383-393, 2012.
29. Miquel-Serra L, Serra M, Hernández D, Domenzain C, Docampo MJ, Rabanal RM, de Torres I, Wight TN, Fabra A and Bassols A: V3 versican isoform expression has a dual role in human melanoma tumour growth and metastasis. Lab Invest 86(9): 889-901, 2006.
30. Evanko SP, Potter-Perigo S, Bollyky PL, Nepom GT and Wight TN: Hyaluronan and versican in the control of human T-lymphocyte adhesion and migration. Matrix Biol 31(2): 90-100, 2012.
31. Skandalis SS, Kletsas D, Kyriakopoulou D, Stavropoulos M and Theocharis DA: The greatly increased amounts of accumulated versican and decorin with specific post-translational modifications may be closely associated with the malignant phenotype of pancreatic cancer. Biochim Biophys Acta 1760(8): 1217-1225, 2006.
32. Tsara ME, Theocharis AD and Theocharis DA: Compositional and structural alterations of proteoglycans in human rectum carcinoma with special reference to versican and decorin. Anticancer Res 22(5): 2893-2898, 2002.
33. Theocharis AD: Human colon adenocarcinoma is associated with specific post-translational modifications of versican and decorin. Biochim Biophys Acta 1588 (2): 165-172, 2002.
34. Becker L, Huang Q and Mashimo H: Immunostaining of LGR5, an intestinal stem cell marker, in normal and premalignant human gastrointestinal tissue. Sci World J 8: 1168-1176, 2008.
35. + liver stem cells induced by Wnt-driven regeneration. Nature 494 (7436): 247-250, 2013.
36. Uchida H, Yamazaki K, Fukuma M, Yamada T, Hayashida T, Hasegawa H, Kitajima M, Kitagawa Y and Sakamoto M: Over-expression of leucine-rich repeat-containing G protein-coupled receptor 5 in colorectal cancer. Cancer Sci 101(7): 1731-1737, 2010.
37. Kleist B, Xu L, Li G and Kersten C: Expression of the adult intestinal stem cell marker Lgr5 in the metastatic cascade of colorectal cancer. Int J Clin Exp Pathol 4(4): 327-335, 2011.
38. Nakata S, Campos B, Bageritz J, Bermejo JL, Becker N, Engel F, Acker T, Momma S, Herold-Mende C, Lichter P, Radlwimmer B and Goidts V: LGR5 is a marker of poor prognosis in glioblastoma and is required for survival of brain cancer stemlike cells. Brain Pathol 23(1): 60-72, 2013.
39. + cells correlates with gastric cancer progression. PLoS One 7(4): e35486, 2012.
40. Wu XS, Xi HQ and Chen L: LGR5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival. World J Surg Oncol 10: 244, 2012.
41. Pyagay P, Heroult M, Wang Q, Lehnert W, Belden J, Liaw L, Friesel RE and Lindner V: Collagen triple helix repeat containing 1, a novel secreted protein in injured and diseased arteries, inhibits collagen expression and promotes cell migration. Circ Res 96(2): 261-268, 2005.
42. Tang L, Dai DL, Su M, Martinka M, Li G and Zhou Y: Aberrant expression of collagen triple helix repeat containing 1 in human solid cancers. Clin Cancer Res 12(12): 3716-3722, 2006.
43. Palma M, Lopez L, García M, de Roja N, Ruiz T, García J, Rosell E, Vela C, Rueda P and Rodriguez MJ: Detection of collagen triple helix repeat containing-1 and nuclear factor (erythroid-derived 2)-like 3 in colorectal cancer. BMC Clin Pathol 12: 2, 2012.
44. Tan F, Liu F, Liu H, Hu Y, Liu D and Li G: CTHRC1 is associated with peritoneal carcinomatosis in colorectal cancer: A new predictor for prognosis. Med Oncol 30(1): 473, 2013.
45. Alper SL and Sharma AK: The SLC26 gene family of anion transporters and channels. Mol Aspects Med 34(2- 3): 494-515, 2013.
46. Yusa A, Miyazaki K, Kimura N, Izawa M and Kannagi R: Epigenetic silencing of the sulfate transporter gene DTDST induces sialyl Lewisx expression and accelerates proliferation of colon cancer cells. Cancer Res 70(10): 4064-4073, 2010.
47. Galamb O, Sipos F, Solymosi N, Spisák S, Krenács T, Tóth K, Tulassay Z and Molnár B: Diagnostic mRNA expression patterns of inflamed, benign, and malignant colorectal biopsy specimen and their correlation with peripheral blood results. Cancer Epidemiol Biomarkers Prev 17(10): 2835-2845, 2008.
48. Lal-Nag M and Morin PJ: The claudins. Genome Biol 10(8): 235, 2009.
49. Katoh M and Katoh M: CLDN23 gene, frequently down-regulated in intestinal-type gastric cancer, is a novel member of the CLAUDIN gene family. Int J Mol Med 11(6): 683-689, 2003.
50. Gassler N, Schneider A, Kopitz J, Schnölzer M, Obermüller N, Kartenbeck J, Otto HF and Autschbach F: Impaired expression of acyl-CoA-synthetase 5 in epithelial tumours of the small intestine. Hum Pathol 34(10): 1048-1052, 2003.
51. Yeh CS, Wang JY, Cheng TL, Juan CH, Wu CH and Lin SR: Fatty acid metabolism pathway play an important role in carcinogenesis of human colorectal cancers by microarraybioinformatics analysis. Cancer Lett 233(2): 297-308, 2006.
52. Mashima T, Sato S, Okabe S, Miyata S, Matsuura M, Sugimoto Y, Tsuruo T and Seimiya H: Acyl-CoA synthetase as a cancer survival factor: its inhibition enhances the efficacy of etoposide. Cancer Sci 100 (8): 1556-1562, 2009.
53. Gassler N, Roth W, Funke B, Schneider A, Herzog F, Tischendorf JJ, Grund K, Penzel R, Bravo IG, Mariadason J, Ehemann V, Sykora J, Haas TL, Walczak H, Ganten T, Zentgraf H, Erb P, Alonso A, Autschbach F, Schirmacher P, Knüchel R and Kopitz J: Regulation of enterocyte apoptosis by acyl-CoA synthetase 5 splicing. Gastroenterology 133(2): 587-598, 2007.
54. Bamburg JR and Wiggan OP: ADF/cofilin and actin dynamics in disease. Trends Cell Biol 12 (12): 598-605, 2002.
55. Papadopoulou N, Charalampopoulos I, Alevizopoulos K, Gravanis A and Stournaras C: RHO/ROCK/actin signaling regulates membrane androgen receptor induced apoptosis in prostate cancer cells. Exp Cell Res 314(17): 3162-3174, 2008.
56. Lefranc F, Sauvage S, Van Goietsenoven G, Mégalizzi V, Lamoral-Theys D, Debeir O, Spiegl-Kreinecker S, Berger W, Mathieu V, Decaestecker C and Kiss R: Narciclasine, a plant growth modulator, activates RHO and stress fibers in glioblastoma cells. Mol Cancer Ther 8(7): 1739-1750, 2009.
57. Yu J, Liang QY, Wang J, Cheng Y, Wang S, Poon TC, Go MY, Tao Q, Chang Z and Sung JJ: Zinc-finger protein 331, a novel putative tumour suppressor, suppresses growth and invasiveness of gastric cancer. Oncogene 32(3): 307-317, 2013.
58. denDekker AD, Xu X, Vaughn MD, Puckett AH, Gardner LL, Lambring CJ, Deschenes L and Samuelson DJ: Rat Mcs1b is concordant to the genome-wide association-identified breast cancer risk locus at human 5q11.2 and MIER3 is a candidate cancer susceptibility gene. Cancer Res 72(22): 6002-6012, 2012.
59. Cancer Genome Atlas Network: Comprehensive molecular characterization of human colon and rectal cancer. Nature 487(7407): 330-337, 2012.
60. Zassadowski F, Rochette-Egly C, Chomienne C and Cassinat B: Regulation of the transcriptional activity of nuclear receptors by the MEK/ERK1/2 pathway. Cell Signal 24(12): 2369-2377, 2012.
61. Wang Q, Ding Q, Dong Z, Ehlers RA and Evers BM: Downregulation of mitogen-activated protein kinases in human colon cancers. Anticancer Res 20(1A): 75-83, 2000.
62. Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, Li N, Berriz GF, Gibbons FD, Dreze M, Ayivi-Guedehoussou N, Klitgord N, Simon C, Boxem M, Milstein S, Rosenberg J, Goldberg DS, Zhang LV, Wong SL, Franklin G, Li S, Albala JS, Lim J, Fraughton C, Llamosas E, Cevik S, Bex C, Lamesch P, Sikorski RS, Vandenhaute J, Zoghbi HY, Smolyar A, Bosak S, Sequerra R, Doucette-Stamm L, Cusick ME, Hill DE, Roth FP and Vidal M: Towards a proteome-scale map of the human protein - protein interaction network. Nature 437(7062): 1173-1178, 2005.
63. Fei P, Yin J and Wang W: New advances in the DNA damage response network of Fanconi anemia and BRCA proteins. FAAP95 replaces BRCA2 as the true FANCB protein. Cell Cycle 4(1): 80-86, 2005.
64. Ono Y and Sorimachi H: Calpains: An elaborate proteolytic system. Biochim Biophys Acta 1824(1): 224-236, 2012.
65. Harris F, Biswas S, Singh J, Dennison S and Phoenix DA: Calpains and their multiple roles in diabetes mellitus. Ann NY Acad Sci 1084: 452-480, 2006.
66. Frances CP, Conde MC, Saez ME, Diez SF, Rey CM, Ramírez-Armengol JA, Pascual MH, Gonzalez-Perez A, Torres PP, Real LM, Serrano-Rios M, López JL, Ruiz A and Royo JL: Identification of a protective haplogenotype within CAPN10 gene influencing colorectal cancer susceptibility. J Gastroenterol Hepatol 22(12): 2298-2302, 2007.